Richard Fedorak

Metabolomic Technologies Inc. (MTI) is a Canadian biotechnology company founded by the late Dr. Richard Fedorak to commercialize metabolomics-based diagnostic solutions for gastrointestinal diseases. The company's lead product, PolypCheck, is a non-invasive urine-based test designed to detect colonic adenomatous polyps, which are key precursors to colorectal cancer. By utilizing mass spectrometry and proprietary metabolic profiling, MTI provides a patient-friendly screening alternative that aims to improve early detection rates and reduce the reliance on invasive procedures. Based in Edmonton, Alberta, MTI continues to leverage its metabolomics platform to develop additional diagnostic tools for conditions such as inflammatory bowel disease.